To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Survivin in autoimmune di… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Survivin in autoimmune diseases.

Review article
Authors Giacomo Gravina
Caroline Wasén
Maria-Jose Garcia-Bonete
Minna Turkkila
Malin Erlandsson
Sofia Silfverswärd Lindblad
Mikael Brisslert
Rille Pullerits
Karin Andersson
Gergely Katona
Maria Bokarewa
Published in Autoimmunity reviews
Volume 16
Issue 8
Pages 845-855
ISSN 1873-0183
Publication year 2017
Published at Institute of Medicine, Department of Rheumatology and Inflammation Research
Department of Chemistry and Molecular Biology
Pages 845-855
Language en
Subject categories Rheumatology and Autoimmunity


Survivin is a protein functionally important for cell division, apoptosis, and possibly, for micro-RNA biogenesis. It is an established marker of malignant cell transformation. In non-malignant conditions, the unique properties of survivin make it indispensable for homeostasis of the immune system. Indeed, it is required for the innate and adaptive immune responses, controlling differentiation and maintenance of CD4(+) and CD8(+) memory T-cells, and in B cell maturation. Recently, survivin has emerged as an important player in the pathogenesis of autoimmune diseases. Under the conditions of unreserved inflammation, survivin enhances antigen presentation, maintains persistence of autoreactive cells, and supports production of autoantibodies. In this context, survivin takes its place as a diagnostic and prognostic marker in rheumatoid arthritis, psoriasis, systemic sclerosis and pulmonary arterial hypertension, neuropathology and multiple sclerosis, inflammatory bowel diseases and oral lichen planus. In this review, we summarise the knowledge about non-malignant properties of survivin and focus on its engagement in cellular and molecular pathology of autoimmune diseases. The review highlights utility of survivin measures for clinical applications. It provides rational for the survivin inhibiting strategies and presents results of recent reports on survivin inhibition in modern therapies of cancers and autoimmune diseases.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?